Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

enGene Therapeutics is a promising company in the biotechnology sector with its novel approach to gene therapy delivery, specifically targeting mucosal tissues and other organs. With its lead candidate, detalimogene, showing potential in treating non-muscle invasive bladder cancer (NMIBC), the company has a strong near-term milestone in its complete 12-month CR readout and pre-BLA meeting in 2026. While there are questions concerning the durability and efficacy of detalimogene, enGene has a clear regulatory path with its 54% any-time CR rate and is also exploring additional options through its polidocanol bladder rinse cohort. Despite the recent decline in efficacy reported, enGene has a compelling opportunity in the NMIBC market, but uncertainty remains on the regulatory bar and the company's path forward.

Bears say

enGene Therapeutics is facing several risks as an early development-stage biopharmaceutical company. These include potential failure to demonstrate efficacy in clinical trials, delays in regulatory approvals, and competition from companies with greater resources. Additionally, the company's lead product, detalimogene, may have weaker-than-expected durability and an unclear mechanism of action, leading to a more conservative outlook for its commercial potential. With lower market share and probability of success assumptions, we believe the company's stock may struggle to reach its previous price targets.

ENGN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 8 analysts, ENGN has a Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.